Advancing Clinical Trials & Medical Research in Los Angeles, California
Located at 6333 Wilshire Blvd, Suite 501, the Clinical Research Institute (CRI) is a premier clinical trial facility specializing in Phase I–IV research. Under the guidance of Dr. David Kudrow —a leading neurologist with over 25 years of excellence in migraine, Alzheimer's, neuropathy, and metabolic research—we connect patients with breakthrough medical therapies in partnership with top global biopharmaceutical pioneers.
Medical Direction
David Kudrow, M.D.
PRINCIPAL INVESTIGATOR & NEUROLOGIST IN LOS ANGELES
25+ Years of Research Excellence
Proven track record in medical research management and clinical trial oversight led by Dr. David Kudrow across neurology and therapeutic studies.
Global Biopharma Network
Trusted clinical trial partner for global leaders including Pfizer, Eli Lilly, AbbVie, AstraZeneca, Amgen, Biogen, and Merz.
Patient-Centric Clinical Care
Comprehensive health monitoring, expert investigational care, and strict IRB-backed safety protocols.
Wilshire Blvd Clinical Center
Conveniently situated at 6333 Wilshire Blvd, providing accessible medical research trials across Greater Los Angeles.
David Kudrow, M.D.
PRINCIPAL INVESTIGATOR & NEUROLOGIST IN LOS ANGELES
Meet Our Principal Investigator
Pioneering Neurologist & Medical Research Director in Los Angeles, California
David Kudrow, M.D., is a board-certified neurologist by the American Board of Psychiatry and Neurology (ABPN). He specializes in headache medicine as Director of the California Medical Clinic for Headache in Santa Monica—founded in 1971 by Dr. Lee Kudrow as the first private headache center in the Western United States. Dr. Kudrow earned his medical degree from the USC Keck School of Medicine and completed his neurology residency and clinical neurophysiology fellowship at Harbor-UCLA Medical Center, where he directed the outpatient headache clinic for 23 years.
As Principal Investigator at Clinical Research Institute located at 6333 Wilshire Blvd, Dr. Kudrow has overseen dozens of pivotal Phase I through IV clinical trials. His work encompasses FDA-regulated research across neurological and metabolic conditions—including migraines, Alzheimer's disease, epilepsy, diabetic and non-diabetic neuropathy, and weight loss—partnering with world-renowned pharmaceutical pioneers such as Pfizer, Eli Lilly, AbbVie, AstraZeneca, Amgen, Biogen, Merz. He has authored numerous peer-reviewed medical journals and is a recognized national speaker on migraine therapeutics, advanced neurological care, and clinical research innovation.
100+ Clinical Trials Led
Proven leadership in FDA Phase I–IV clinical trials for migraines, Alzheimer's, epilepsy, neuropathy, and weight loss.
Protocol & GCP Compliance
Expert execution of clinical research protocols meeting rigorous FDA, IRB, and Good Clinical Practice standards.
23 Years at Harbor-UCLA
Decades of clinical excellence leading outpatient neurological care and specialized headache clinics in California.
ABPN Board Certified
Uncompromising dedication to patient safety, ethical research standards, and high-integrity medical data.
Leading Pharmaceutical Sponsors & Global Collaborators
Therapeutic Areas & Research Indications
Led by Dr. David Kudrow at 6333 Wilshire Blvd, the Clinical Research Institute conducts groundbreaking Phase I–IV clinical trials across specialized neurological, metabolic, and chronic pain conditions in Los Angeles, CA.
Migraines & Chronic Headaches
Evaluating acute treatments, innovative preventative therapies, and advanced biologics for episodic and chronic migraines. Our studies focus on reducing attack frequency, severity, and improving patient quality of life.
Sub-Specialties & Clinical Focus
Alzheimer’s Disease & Cognitive Health
Investigating next-generation therapeutics aimed at early detection, slowing cognitive decline, and targeting underlying pathology of Alzheimer’s disease to preserve memory and daily independence.
Sub-Specialties & Clinical Focus
Epilepsy & Seizure Disorders
Testing novel anti-seizure medications (AEDs) and advanced neuromodulatory therapies designed for patients seeking improved seizure control with minimized side effects and better tolerability.
Sub-Specialties & Clinical Focus
Neuropathy (Diabetic & Non-Diabetic)
Dedicated FDA-regulated clinical trials examining targeted pharmaceuticals for peripheral nerve damage, nerve regeneration, and neuropathic pain management caused by diabetes or idiopathic conditions.
Sub-Specialties & Clinical Focus
Weight Loss & Metabolic Health
Researching advanced metabolic pharmaceuticals, GLP-1 receptor agonists, and next-generation therapies focused on sustainable weight management and associated metabolic health conditions.
Sub-Specialties & Clinical Focus
Clinical Study Phases
We conduct rigorous clinical trials from Phase 2 through Phase 4, bridging the gap between intermediate efficacy evaluation and life-changing real-world patient care.
Mid-stage research studies
Mid-stage research testing whether an experimental treatment works while continuing safety monitoring. It is structured into Phase 2a (pilot proof-of-concept for initial efficacy and dosing) and Phase 2b (larger study to confirm the optimal dose and gather robust effectiveness data).
Participants
Usually involves 100 to 300 people who have the target disease or condition.
Duration
Typically lasts from several months up to two years.
Main Goal
To evaluate therapeutic effectiveness (efficacy) and determine common short-term side effects or optimal dosing.
Large-scale studies
Large-scale trials designed to definitively confirm treatment effectiveness, closely monitor side effects, and compare it directly against existing standard therapies. It stands as the final critical step before submitting the drug for regulatory approval.
Participants
Usually involves 1,000 to 3,000+ people who have the target disease or condition.
Duration
Typically lasts from one to several years to observe long-term safety and effectiveness.
Main Goal
To prove statistical evidence of efficacy, confirm safety across a diverse population, and establish the benefit-to-risk ratio.
Real-world monitoring
Post-marketing surveillance conducted after a drug or device receives regulatory approval and reaches the general public. Its purpose is to monitor long-term safety, detect rare risks, evaluate drug interactions, and expand tracking into broader demographics or new therapeutic uses.
Participants
Involves thousands to millions of people in real-world settings.
Duration
Ongoing and long-term, often lasting for several years.
Main Goal
To monitor long-term safety, rare side effects, and real-world effectiveness that could not be detected in smaller, highly controlled clinical trials.
Our Clinical Studies
Explore our ongoing clinical trials officially registered on ClinicalTrials.gov.
Randomized, multicenter clinical trial to compare the effectiveness, tolerability, and persistence of three preventive treatments (Atogepant, Propranolol, and Topiramate) in 1,335 adult patients.
Double-blind clinical study focused on evaluating pharmacodynamics, clinical safety, and monthly migraine episode reduction in adults through the administration of EVO756.
Long-term safety study (approximately 1 year) to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
Outpatient evaluation of the efficacy, safety, and tolerability of elismetrep compared with placebo in the acute treatment of moderate or severe migraine attacks in 1,800 patients.
Single-arm, open-label study to evaluate the safety, tolerability, and effectiveness of redosing rimegepant 75 mg ODT for residual pain or headache relapse.
Randomized, double-blind, placebo-controlled 2-arm study to investigate the prevention of chronic migraine with once-daily rimegepant.
One-year, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of SPN-817 in adults who previously completed a double-blind clinical study.
Find Out If You Qualify for a Clinical Study in Los Angeles
Receive a specialized medical evaluation and access novel treatments for migraines, Alzheimer's, neuropathy, and neurological conditions at our state-of-the-art Wilshire Blvd facility.
Patient Experience & Clinical Trial FAQs
We prioritize patient safety, informed consent, and comprehensive medical care throughout every phase of our clinical trials at 6333 Wilshire Blvd.
Why Participate in a Clinical Trial at CRI?
Access to Advanced Treatments
Receive novel investigational treatments and cutting-edge therapies for migraines, Alzheimer's, and neuropathy before they are broadly available.
Study-Related Care & Medication
All study-related doctor consultations, lab work, diagnostics, and investigational medications are fully covered by study sponsors without insurance requirements.
Expert Neurological Monitoring
Benefit from continuous health monitoring and personalized care by board-certified neurologist Dr. David Kudrow and expert clinical trial staff.
Financial Compensation Provided
Qualifying study participants receive financial compensation and stipends for their time, travel, and research participation.
Advanced Clinical Trials in Los Angeles
Dr. David Kudrow
HEADACHE & MIGRAINE SPECIALIST
Frequently Asked Questions About Clinical Research
Ready to Find Out If You Qualify for a Clinical Study in Los Angeles?
Fill out our brief medical evaluation form and our clinical coordination team in Los Angeles, CA will review your eligibility.
Site Capabilities for Biopharmaceutical Sponsors & Global CROs
Led by Dr. David Kudrow at 6333 Wilshire Blvd, the Clinical Research Institute provides global trial partners with rapid site startup, rigorous GCP/FDA compliance, and privileged access to Los Angeles’ diverse patient demographics.
Metropolitan Demographic Reach
Prime Los Angeles location on Wilshire Blvd, serving a diverse multi-ethnic metropolitan population of over 10 million to drive robust clinical trial recruitment.
Accelerated Trial Startup
Streamlined central IRB submissions, expedited contract execution, and efficient patient pre-screening to achieve immediate site activation and rapid enrollment.
Data Quality & Integrity
Timely electronic data capture (EDC) entry, swift resolution of monitoring queries, and an uncompromising commitment to protocol compliance and patient safety.
Advanced Facility & Equipment
Dedicated investigational product (IP) storage with 24/7 continuous temperature monitoring, on-site centrifugation, -20°C/-80°C cold storage, and private patient examination rooms.
Start Your Medical Evaluation at Our Los Angeles Research Facility
Equipped with cutting-edge medical infrastructure at 6333 Wilshire Blvd in Los Angeles, CA, our facility ensures patient safety and trial precision. Fill out our brief evaluation form today to check your qualification.
10M+
Los Angeles Metro Area Reach
25+ Yrs
Phase I–IV Trial Execution
100%
Protocol Compliance Rate
